ObjectiveTo systematically evaluate the efficacy and safety of human albumin for the treatment of acute pancreatitis (AP). MethodsThe databases of PubMed, Web of Science, China National Knowledge Infrastructure, VIP, and Wanfang Data Knowledge Service Platform were retrieved by computer for enrolling randomized controlled trials and cohort studies of human albumin for treating AP. After literature screening and quality evaluation, Meta-analysis was performed by using RevMan 5.4 software. ResultsA total of 15 literature was eventually enrolled, and there were 2047 patients. The results of Meta-analysis revealed that compared with the control group, the experiment group exhibited shorter time for relief of abdominal pain and distension, shorter time for length of hospital stay, decreased levels of inflammation-related indices, and decreased incidence rates of pancreatic pseudocyst, seroperitoneum, and abdominal infection (P＜0.05). However, no statistically significant difference in the incidence rate of acute kidney failure was found between the two groups (P＞0.05). ConclusionHuman albumin therapy can shorten duration of clinical symptoms sustaining in AP patients, decrease levels of inflammation-related indices, shorten length of hospital stay, ameliorate patients′ prognosis, and dose not increase occurrence risk of related complications.

无